Feedback

Eight pharmacokinetic genetic variants are not associated with the risk of bleeding from direct oral anticoagulants in non-valvular atrial fibrillation patients

Affiliation
Department of Clinical Pharmacy ,College of Pharmacy ,University of Michigan ,Ann Arbor ,MI ,United States
Campos-Staffico, Alessandra M.;
Affiliation
Department of Clinical Pharmacy ,College of Pharmacy ,University of Michigan ,Ann Arbor ,MI ,United States
Dorsch, Michael P.;
Affiliation
Division of Cardiovascular Medicine ,Department of Internal Medicine ,University of Michigan ,Ann Arbor ,MI ,United States
Barnes, Geoffrey D.;
Affiliation
Department of Clinical Pharmacy ,College of Pharmacy ,University of Michigan ,Ann Arbor ,MI ,United States
Zhu, Hao-Jie;
Affiliation
Department of Neurology ,School of Medicine ,University of Alabama at Birmingham ,Birmingham ,AL ,United States
Limdi, Nita A.;
Affiliation
Department of Clinical Pharmacy ,College of Pharmacy ,University of Michigan ,Ann Arbor ,MI ,United States
Luzum, Jasmine A.

Background: Atrial fibrillation (AF) is the leading cause of ischemic stroke and treatment has focused on reducing this risk through anticoagulation. Direct Oral Anticoagulants (DOACs) are the first-line guideline-recommended therapy since they are as effective and overall safer than warfarin in preventing AF-related stroke. Although patients bleed less from DOACs compared to warfarin, bleeding remains the primary safety concern with this therapy. Hypothesis: Genetic variants known to modify the function of metabolic enzymes or transporters involved in the pharmacokinetics (PK) of DOACs could increase the risk of bleeding. Aim: To assess the association of eight, functional PK-related single nucleotide variants (SNVs) in five genes ( ABCB1 , ABCG2 , CYP2J2 , CYP3A4 , CYP3A5 ) with the risk of bleeding from DOACs in non-valvular AF patients. Methods: A retrospective cohort study was carried out with 2,364 self-identified white non-valvular AF patients treated with either rivaroxaban or apixaban. Genotyping was performed with Illumina Infinium CoreExome v12.1 bead arrays by the Michigan Genomics Initiative biobank. The primary endpoint was a composite of major and clinically relevant non-major bleeding. Cox proportional hazards regression with time-varying analysis assessed the association of the eight PK-related SNVs with the risk of bleeding from DOACs in unadjusted and covariate-adjusted models. The pre-specified primary analysis was the covariate-adjusted, additive genetic models. Six tests were performed in the primary analysis as three SNVs are in the same haplotype, and thus p -values below the Bonferroni-corrected level of 8.33e-3 were considered statistically significant. Results: In the primary analysis, none of the SNVs met the Bonferroni-corrected level of statistical significance (all p > 0.1). In exploratory analyses with other genetic models, the ABCB1 (rs4148732) GG genotype tended to be associated with the risk of bleeding from rivaroxaban [HR: 1.391 (95%CI: 1.019–1.900); p = 0.038] but not from apixaban ( p = 0.487). Conclusion: Eight functional PK-related genetic variants were not significantly associated with bleeding from either rivaroxaban or apixaban in more than 2,000 AF self-identified white outpatients.

Graphical Abstract

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: Copyright © 2022 Campos-Staffico, Dorsch, Barnes, Zhu, Limdi and Luzum.

Use and reproduction: